Table 1.
Comparison of response rates amongst completed clinical trials for pomalidomide in myelofibrosis
| Reference | Phase | Dosing regimen and sample size | Sample size (n) | Criteria | Anemia improvement (%) | Splenomegaly improvement (%) |
|---|---|---|---|---|---|---|
| Tefferi et al53 | II | Pomalidomide 0.5 mg + prednisone | 22 | IWG-MRT | 36 | 0 |
| Pomalidomide 2 mg alone | 22 | IWG-MRT | 23 | 0 | ||
| Prednisone alone | 21 | IWG-MRT | 19 | 0 | ||
| Pomalidomide 2 mg + prednisone | 19 | IWG-MRT | 16 | 0 | ||
| Mesa et al54 | I/II | Pomalidomide 0.5 mg | 2 | IWG-MRT | 63 | 29 |
| Pomalidomide ≥2.5 mg | 11 | IWG-MRT | 18 | 22 | ||
| Begna et al55 | II | Pomalidomide 0.5 mg | 58 | IWG-MRT | 17 | 0 |
| Daver et al57 | II | Pomalidomide 3.0 mg | 21 | IWG-MRT CI | NR | NR |
| Pomalidomide 0.5 mg | 29 | Delphi | 10 | 0 | ||
| Daver et al58 | II | Pomalidomide 0.5 mg + prednisone | 29 | Delphi | 22 | 0 |
Abbreviations: CI, clinical improvement; IWG-MRT, International Working Group for Myelofibrosis Research and Treatment; NR, not reported.